What Furiex Pharmaceuticals, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Almenoff June Sherie | President | Jul 02 | Disposition to Issuer · D | −24,600 | — | — | 0 |
| Forest Laboratories Inc | 10% owner | Jul 02 | Open-market buy · P | +11,169,066 | $95.00 | +$1.06B | 0 |
| Dixon Wendy L | Director | Jul 02 | Disposition to Issuer · D | −7,160 | — | — | 0 |
| Davis Stephen | Director | Jul 02 | Disposition to Issuer · D | −9,308 | — | — | 0 |
| Kaldor Stephen W | Director | Jul 02 | Disposition to Issuer · D | −7,160 | — | — | 0 |
| Patel Sailash | Chief Financial Officer | Jul 02 | Disposition to Issuer · D | −26,444 | — | — | 0 |
| Corr Peter B | Director | Jul 02 | Disposition to Issuer · D | −8,447 | — | — | 0 |
| McIntyre Gail Frances | Senior Vice President-Research | Jul 02 | Disposition to Issuer · D | −24,318 | — | — | 0 |
| Covington Paul S | Senior VP-Clinical Operations | Jul 02 | Disposition to Issuer · D | −22,523 | — | — | 0 |
| Eshelman Fredric N | Director | Jul 02 | Disposition to Issuer · D | −140 | — | — | 0 |
| Eshelman Fredric N | Director | Jul 02 | Disposition to Issuer · D | −41,666 | — | — | 0 |
| Eshelman Fredric N | Director | Jul 02 | Disposition to Issuer · D | −132,689 | — | — | 0 |
| Eshelman Fredric N | Director | Jul 02 | Disposition to Issuer · D | −2,673,522 | — | — | 0 |
| Covington Paul S | Senior VP-Clinical Operations | Jun 24 | Open-market sale · S | −10,368 | $104.12 | −$1.08M | 22,523 |
| Covington Paul S | Senior VP-Clinical Operations | Jun 24 | Exercise / conversion · M | +10,368 | $17.80 | +$185K | 32,891 |
| Patel Sailash | Chief Financial Officer | Jun 24 | Open-market sale · S | −32,928 | $104.00 | −$3.42M | 26,444 |
| Patel Sailash | Chief Financial Officer | Jun 24 | Exercise / conversion · M | +32,928 | $9.11 | +$300K | 59,372 |
| Covington Paul S | Senior VP-Clinical Operations | Jun 18 | Open-market sale · S | −45,691 | $104.11 | −$4.76M | 22,523 |
| Covington Paul S | Senior VP-Clinical Operations | Jun 18 | Exercise / conversion · M | +45,691 | $9.11 | +$416K | 68,214 |
| McIntyre Gail Frances | Senior Vice President-Research | Jun 17 | Open-market sale · S | −8,008 | $105.00 | −$841K | 24,318 |
Loading...
